Identity and synonyms
P21 is an ambiguous short name; confirm P021 chemical identity and distinguish unrelated p21 protein.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide mimetic
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
CNTF-related peptide mimetic; BDNF/neuroplasticity hypotheses.
Evidence and critical reading
Reported scientific and empirical uses
Cognition and neurology
CNTF-related mimetic also written P21; distinguish it from p21 protein.
Human evidence
No controlled human efficacy finding was verified for the exact catalog identity in this screen.
Preclinical evidence
Cell and mouse models of CDKL5 deficiency; not a human cognition trial.
Critical reading and limitations
Selected work is cell/mouse CDKL5-deficiency research, not a human cognition trial.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Human safety, contraindications and interactions are not adequately established for the catalog product. Missing reports are not evidence of safety.
Experimental BDNF increases do not establish human dosing/safety.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
P21 · 9 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT04284774 · Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialRegistry status: Active, not recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT03155620 · Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Registry status: Active, not recruitingLast update posted: July 24, 2026Query verification: October 16, 2026
NCT04914845 · KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid LeukemiaRegistry status: CompletedLast update posted: January 27, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID39592934
Mottolese N, Loi M, Trazzi S, Tassinari M, Uguagliati B, Candini G, Iqbal K, Medici G, Ciani E.
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026